Utilization, cost, and specialty distribution of topical ruxolitinib prescribing in Medicare Part D, 2018-2024: A cross-sectional study

JAAD International · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles